REVIEW ARTICLE

A SITUATIONAL ANALYSIS OF ANTIMICROBIAL DRUG RESISTANCE IN AFRICA: ARE WE LOSING THE BATTLE?

Andrew Nyerere Kimang’a

ABSTRACT

BACKGROUND: The first arrival of a sizable shipment of penicillin at the North African Theatre of Operations for USA military use in 1943 was a landmark that turned a new chapter of antibiotic use in Africa. Over the past decade the expansion of resources and the technological advances have meant that much larger quantities of drugs are available in developing countries than ever before. As a result, many more individuals are receiving necessary treatment or therapy than just ten years ago. This very welcome event is accompanied by the terrible irony that increases in drug availability and use can promote drug resistance and render the same life-saving drugs ineffective.

METHODS: The study focused on bacterial pathogens. One hundred and three relevant literatures were identified from the PubMed online database. The coverage included research articles concerning antimicrobial resistance involving subjects of an African country.

RESULTS: Resistant bacteria are on a war path and evidently have acquired an edge over us. Our actions are evidently fuelling the resistance. The indiscriminate use of antibiotics in humans and livestock, wrong and substandard prescriptions by unqualified ‘medical personnel’ together with poor diagnosis or lack of it are all adding fuel to the already fired train of resistant microbes.

CONCLUSION: To win the war and turn tables as we did with the discovery of penicillin and other antimicrobials in the 1940s, then we must all act now. Antimicrobial stewardship programs – Education, training of laboratory personnel and investment in laboratory infrastructure development are desirable in these situations

KEYWORDS: Antibiotics, Resistance, Bacteria

INTRODUCTION

The discovery of penicillin by Alexander Fleming in 1928 (1) and the subsequent administration of its first dose in clinical practice in 1941 (2, 3, 4, 5, 6) marked a landscape shift in patient care. The success of antimicrobials against disease-causing microbes is among modern medicine’s greatest achievements (7). After more than 70 years of widespread use, however, many antimicrobials are not as effective as they used to be. The mass production of penicillin near the end of the Second World War (8) ushered in the era of modern antibiotics, causing a paradigm shift in the way we view pathogenic bacterial infection.

The first arrival of a sizable shipment of penicillin at the North African Theatre of Operations for USA military use in 1943 (9) was a landmark that turned a new chapter of antibiotic use in Africa. Over the past decade the expansion of resources and the technological advances have meant that much larger quantities of drugs are available in developing countries than ever before. As a result, many more individuals are receiving necessary treatment or therapy than just ten years ago. This very welcome event is accompanied by poor practices that promote drug resistance (10). Resistance to common antimicrobials affects diseases that have not received dedicated increases in funding over the past decade. Examples include pathogens such as *Shigella* and *Vibrio cholerae* and *Streptococcus pneumoniae*. These diseases are major causes of childhood death in Sub-Saharan Africa (11).
Antibiotics are among the most commonly prescribed drugs in hospitals (12). In Africa, about 90.1% of individuals seek care outside the home, of these, 94.7% take medicines and 36.2% receive antibiotics. Of all those who receive antibiotics, 31.7% do not receive a prescription from a doctor and about 26.4% obtain antibiotics from an informal dispenser (13). Evidently, antibiotics are widely and inappropriately used in Africa resulting to antibiotic resistance. This situation impinges on the quality of patient care through its associated mortality, morbidity, and significant economic consequences (14). Since antibiotics are the most commonly prescribed drugs in hospitals and their use is one of the important factors for the development and spread of resistance in the hospitals, an audit of their susceptibility patterns is important in implementation of rational empirical antibiotic strategy.

MATERIALS AND METHODS

The study focused on bacterial pathogens. Relevant literature was identified from the PubMed online database. Each search was performed on only English language articles using terms like ‘bacterial resistance’, ‘antibiotic use’, ‘antimicrobial resistance’ and ‘bacterial surveillance’ combined with the different countries. Bibliographies of all relevant papers were searched to identify further papers. Only publications listing original data on bacterial resistance in humans were included. The coverage included research articles concerning antimicrobial resistance involving subjects of an African country.

RESULTS

The Global Burden of Antibiotic Resistance: Worldwide, the prevalence of antimicrobial resistance limits the therapeutic options for treatment of infections, and increases the social benefit from disease prevention (15). Antimicrobial resistance contributes to the global specter of a post-antimicrobial era in which some of the most effective tools in the physician’s armamentarium including antibiotics, anti-tuberculosis and anti-malarial drugs lose their effectiveness (16-23). Greater consumption of antibiotics appears to correlate with increases in antibiotic resistance (24). This is most clearly observable in data from the European Surveillance of Antimicrobial Consumption (ESAC) study in Europe (25).

Antibiotic Resistance in Southern Africa: A review of the susceptibility profiles of Neisseria gonorrhoeae over a 20-year period in the Pretoria region (26) best portrays the desperate situation of antibiotics in South Africa. Findings show that Penicillase-producing Neisseria gonorrhoeae strains increased from 4% to 16%, whilst chromosomally mediated penicillin-resistant strains increased dramatically from 0% to 16% from 1984 to 2004. High-level tetracycline-resistant strains (36%) were detected for the first time in 2004. Ciprofloxacin resistance emerged at 7% in the same year. Additionally, Methicillin-resistant (80%) S. aureus (MRSA) continues to be a problem for clinicians (27). Up-regulated resistance to many first and second line antibiotics in K. pneumoniae and S. pneumoniae isolates has been documented as well (28, 29).

In Zimbabwe, there is high resistance to Ampicillin (84.5%) and Cotrimoxazole (68.5%) among the Gram negative bacilli (30). Gram positive cocci show resistance to Nalidixic acid (81%) and Cotrimoxazole (69%) with E. coli showing as high as 84% resistance to ampicillin and 68% to Cotrimoxazole. Over 90% of isolates are resistant to Trimethoprim/Sulfamethoxazole and 16% are resistant to Tetracycline (31).

In Mozambique and Angola, increasing resistance to Ampicillin, Streptomycin, Spectinomycin, Trimethoprim-Sulfisoxazole, Kanamycin, Chloramphenicol, Tetracycline and Gentamycin has been observed (32-35). In patients with no history of prior tuberculosis treatment, the multidrug resistance rate is 3.4% and resistance to isoniazid and Streptomycin (HS) is 5.2% (33). Drug resistance is significantly more common among those with a history of prior treatment.

Antibiotic Resistance in East Africa: In Kenya, the bacterial infections that contribute most to human disease are often those in which resistance is most evident (36). Antibiotic resistance patterns are reportedly up-regulated in persons living with HIV/AIDS (37). Evidently, prolonged exposure to antibiotics makes these individuals harbor strains that are significantly more resistant to antibiotics.
In other studies, 71% *Staphylococcus aureus* isolates from Kenya have demonstrated multiple drug resistance (38). Elsewhere in Kenya, isolates from areas mainly populated by the Maasai community majority of who practice traditional medicine were characterized (39). Overall antibiotic resistance levels was found to be much lower than those reported from the rest of Kenya, possibly due to the lower levels of exposure and usage of antimicrobials among the Maasai community.

In Uganda, resistance to Ampicillin, Amoxicillin and Chloramphenicol has been documented (40). *Staphylococcus aureus* *Pseudomonas aeruginosa*, *Proteus mirabilis* are reportedly multidrug resistant. In western Uganda, most isolates are resistant to the most commonly prescribed antimicrobials (41, 42). Resistance in surgical inpatients is significantly higher than outpatients (43).

In Ethiopia, the situation is much dire. Gonococcal strains have been found to be multidrug resistant (44). Elevated resistance among gastrointestinal pathogens (45) as well as increased and multiple resistance rates to Erythromycin (89.4%), Amoxicillin (86.0%) and Tetracycline (72.6%) have been documented in isolates from urine, ear discharge, pus swab from wounds, and eye discharge (46). Isolates from the cerebrospinal fluids (CSF) as well as urinary pathogens have demonstrated multidrug resistance (47, 48).

Vlieghe et al. (2008) systematically reviewed published literature on bacterial resistance in Central African (Cameroon, Chad, Gabon, São Tomé e Príncipe, Congo-Brazzaville, Democratic Republic of the Congo (DRC) (formerly Zaire), the Central African Republic (CAR), Angola and Equatorial Guinea) countries (49, 50). Significant findings included multidrug resistance in *Shigella* and *Salmonella* spp. and the emergence of Meticillin-resistant *Staphylococcus aureus*, high-level Penicillin-resistant *Streptococcus pneumoniae* and extended-spectrum beta-lactamases among Gram-negative pathogens (50). Clearly, Central African region shares the worldwide trend of increasing antimicrobial resistance.  

**Antibiotic Resistance in West and Northern Africa:** In Egypt, studies have reported Penicillin resistant *S. pneumonia* (51-57). One of the initial studies revealed a low percentage of antimicrobial resistance (54). An increase in penicillin resistance was recorded in a later study where, 0.8% resistance was detected (52). Other studies in Egypt reveal an increase in resistance to most clinical isolates (55, 58, and 59). High rates of multidrug resistance in *S. pneumoniae* have been linked to dispensing of antibiotic which are generally available as an over-the-counter medication (53, 56).

Nigerian isolates show high resistance in both Gram-positive and Gram-negative isolates (60, 61). Examination of antimicrobial susceptibility of *Shigella* spp. and *Escherichia coli*, isolates from diarrheal patients in Nigeria (62, 63) indicate that over 70% of the *Shigella* isolates are resistant to two or more drugs. During 1990–2000, resistance to Ampicillin reportedly increased from 70% to 90%, Co-trimoxazole from 77% to 85%, Chloramphenicol from 71% to 77%, Streptomycin from 71% to 79%, and Nalidixic acid from 0% to 11.3%.

**Root-cause Analysis of antimicrobial resistance in Africa:** The emergence of antimicrobial resistance is primarily due to excessive and often unnecessary use of antibiotics in humans and animals (64-66). But in Africa, the situation is more complex than simple antimicrobial overuse. Increasing antimicrobial resistance in Africa has been exacerbated by multiple factors. For instance, the human resource problem in the health sector in sub-Saharan Africa has reached crisis proportions. A complex set of factors has contributed to this problem, some exogenous, such as the austere fiscal measures introduced by structural adjustment, which often result in cutbacks in the number of health workers. But endogenous factors are also to blame, including misdirected human resource and training policies, weak institutions, and inappropriate structures (67). Conspicuously, there are no adequate laboratory facilities (68-70) and enough trained staff (71-74) to isolate pathogens and perform sensitivity tests so that infectious diseases are treated empirically. This leads to the extensive use of antimicrobial drugs which have favored the emergence of resistant strains.

National laboratory strategic plans that specify the policies that govern laboratories are inadequate. Consequently, information about drug resistance is not properly communicated to those
prescribing antimicrobials and no adequate guidelines regarding the selection of drugs are available (75-80). Additionally, there is no adequate documented local retrospective data on the benches of health care providers to guide good antibiotic stewardship. Compounding this problem is the lack of infection control procedures and wound management in hospitals, resulting in the spread of infectious disease and resistant strains particularly from the environment (81-84).

There are several reports of sub-standard and counterfeit antimalarial drugs circulating in the markets of developing countries (85). About 15% of all drugs in circulation worldwide are believed to be counterfeit, with the figures rising to as high as 50% in some parts of Africa (86). Safety, quality, and efficacy of medicines are the three most important criteria used by governments to regulate pharmaceuticals (87). Quality of drugs is especially important and is one of the earliest to come under governments’ scrutiny (88). In developing countries, the development of national drug policies (89, 90) has been necessary to ensure the availability of quality pharmaceutical products. However, there are still many difficulties in effecting quality assurance measures on pharmaceutical products circulating in the market. Poor quality of drugs has been linked to counterfeiting of medicines (91), chemical instability especially in tropical climate (92) and poor quality control during manufacturing (93).

Other unresolved chemotherapeutic dilemmas have arisen as a result of the AIDS epidemic. For example, there is inconclusive evidence to support or refute the use of Trimethoprime-Sulfisoxazole for the prevention of opportunistic infections in AIDS patients (94, 95). This leads to overuse of antimicrobials in these population and thus propagates resistance. Additionally, HIV infection is associated with primary multi-drug resistant-tuberculosis (96-98).

Patient knowledge, attitude and behavior of antibiotic usage can define nature of antibiotic stewardship. Illiteracy among African populations and lack of antibiotic awareness leads individuals to seek antibiotics for ailments that are naturally self-limiting and or at best caused by other factors and not necessarily bacterial pathogens (99, 100). As well, there is abuse of antibiotic usage in cattle (101) in addition to self-medication with antibiotics among the African population (102, 103).

WAY-FORWARD

Antimicrobial stewardship programs have to be developed as a response to these issues. As antimicrobial resistance increases and the development of new antimicrobial agents declines, it is critical that we use antimicrobials that are still effective wisely and judiciously. Antimicrobial stewardship is a systematic approach to optimizing the use of antimicrobials. It is used by healthcare institutions to reduce inappropriate antimicrobial use, improve patient outcomes and reduce adverse consequences of antimicrobial use.

Education is needed to promote acceptance of antimicrobial stewardship programme strategies and influence prescribing behavior. Education should be provided in conjunction with active intervention because passive education alone is only marginally effective for modifying prescribing behavior. Guidelines and clinical practices that are evidence based and take into consideration local microbiology and antimicrobial resistance patterns may improve antimicrobial use. These guidelines and clinical practices should be developed with multidisciplinary input to improve the likelihood of adherence.

The systemic acute lack of qualified laboratory personnel is a major and severe constraint in implementing and scaling up antibiotic stewardship. In most developing countries, there is a clear correlation between the quality of trained staff and proximity to the capital city. National reference laboratories that are situated in the capital city tend to have more qualified staff than do regional or district-level laboratories. The severe lack of trained laboratory experts at the regional and district levels presents an additional layer of challenge in the rapid expansion and decentralization of prevention and care services to district health centers in areas where most of the population resides. To achieve rapid scale-up of services, the training of laboratory personnel is critical at all levels of the laboratory network.

In many African countries, health facilities and laboratories in particular are reportedly faced with significant infrastructural challenges.
Documentary evidence indicates that these facilities have minimal physical infrastructure, with even the physical building being inadequate for the needs of the laboratory. Moreover, laboratories, when they exist, are reportedly often in a degraded state. Significant investment in laboratory infrastructure development is desirable in these situations. This requires a concerted effort by government and external donors, preferably within a strategic plan.

REFERENCES

1. Fleming A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to their use in Isolation of B. influenza. The Br J Exp Pathol. 1928; 10: 226-236
2. Florey HW, Abraham EP, Gardner AD, Chain E, Fletcher CM, Heatley NG, et al. Further observations on penicillin. Lancet. 1941; 2:6155-66.
3. Fulton JF. Diary. 1942. 1942; 18:9-22. Located at: Medical Historical Library, Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT.
4. Goodman LS, Gilman A. Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan; 1980:1127, figure 50.1
5. Grossman CM. The First Use of Penicillin in the United States. Ann Intern Med. 2008; 149:135-136.
6. Fulton JF, Tager M. Coccidioidomycosis and penicillin. Yale J Biol Med. 1976; 49:391-8. [PMID: 793204]
7. Plotkin MJ, Shnayerson M. The Killers Within: The Deadly Rise of Drug-Resistant Bacteria. 2003.
8. Richards AN. Production of penicillin in the United States (1941–1946). Nature. 1964; 201:441-5.
9. Beecher HK. “Scarce Resources and Medical Advancement,” Daedalus 1969; 98: 275-313, pp. 280-281.
10. Beitha A. Mapping Factors that Drive Drug Resistance (with a Focus on Resource-Limited Settings): A First Step towards Better Informed Policy. Center for Global Development, 2008
11. Mathers CD., Alan DL, Christopher J. Murray L. "The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001." 2006. Global Burden of Disease and Risk Factors, ed. 45-93. New York: Oxford University Press. DOI: 10.1596/978-0-8213-6262-4/Chpt-3.
12. Ravi PS, Praveen P, Nagesh KS, Joshy ME, Kottallur NB. Prescribing patterns of antibiotics and sensitivity patterns of common microorganisms in the Internal Medicine ward of a teaching hospital in Western Nepal: a prospective study. Ann Cli Micro Antimicro. 2003; 2:7
13. Vialle-Valentin CE, LeCates RF, Zhang F, Desta A, Ross-Degnan D. Predictors of antibiotic use in African communities: evidence from medicines household surveys in five countries. Tr Med Int Health. 2012; 17(2): 211–222
14. Kunin CM (1993) Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 118: 557-61.
15. Eggleston K, Ruiifang Z, Richard J. The Global Challenge of Antimicrobial Resistance: Insights from Economic Analysis. Int. J. Environ. Res. Public Health 2010, 7, 3141-3149.
16. Levy SB. Multidrug resistance: A sign of the times. N Engl. J Med. 1998, 338, 1376-1378. 3148
17. Cohen M.L. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science1992, 257, 1050-1055.
18. Bancroft EA. Antimicrobial resistance: it's not just for hospitals. JAMA 2007, 298, 1803.
19. Shah NS, Wright A, Bai GH et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect.Dis. 2007, 13, 380-387
20. Harbarth S, Samore, MH. Antimicrobial resistance determinants and future control. Emerg.Infect. Dis. 2005, 11, 794-801.
21. Moelling RC, Graybill JR, McGowan JE, Corey L. Antimicrobial resistance prevention Initiative-an update: Proceedings of an expert panel on resistance. AJIC 2007, 35, 1-23.
22. Song JH, Jung SI, Ko KS et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP Study). Antimicrob. Agents Chemother. 2004, 48, 2101-2107.
23. Tiemersma EW, Bronzwaer SL, Lyytikainen O et al. European antimicrobial resistance surveillance system participants. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg. Infect. Dis. 2004, 10, 1627-1634.

24. Goossens H. and Lipsitch M. Global Burden of Antimicrobial Resistance. Adv Stud Med. 006;6(7C): S644-S651

25. Goossens H, Ferech M, Vander SR, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365: 579-587.

26. Dangor Y, Jongh M, Adam A, Hoosen A. Antimicrobial susceptibility patterns of gonococcal isolates in Pretoria, South Africa, over a 20-year period (1984-2004). South Afr J Epidemiol Infect 2010; 25(3):10-13

27. Adebayo O, Johnson L. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa. BMC Infectious Diseases 2006, 6:125

28. Heather BJ, Lyen CH, Mark FC, Whitelaw A, Landon M. Bacterial Disease and Antimicrobial Susceptibility Patterns in HIV-Infected, Hospitalized Children: A Retrospective Cohort Study. PLoS ONE. 2008; 3 (9) e3260

29. Liebowitz LD, Slabbert M, Huisamen A. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: Moxifloxacin compared with eight other antimicrobial agents. URI: http://hdl.handle.net/10019.1/13999

30. Mbanga J, Dube S, Munyanduki H. Prevalence and drug resistance in bacteria of the urinary tract infections in Bulawayo province, Zimbabwe. East Afr J Public Health. 2010 7(3): 229-32.

31. Mason PR, Gwanzura L, Latif AS, Marowa E, Ray S, Katzenstein DA. Antimicrobial resistance in gonococci isolated from patients and from commercial sex workers in Harare, Zimbabwe. Int J Antimicrob Agents. 1997 9(3):175-9.

32. Mandomando I, Sigauque B, Morais L, et al. Antimicrobial drug resistance trends of bacteremia isolates in a rural hospital in southern Mozambique. Am J Trop Med Hyg. 2010; 83(1):152-7.

33. Mac-Arthur A, Gloyd S, Perdigão P, Noya A, Sacarlal J, Kreiss J. Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique. Int J Tuberc Lung Dis. 2001; 5(10):894-902.

34. Ferreira E, Costa M, Vaz Pato MV. Resistance to antibiotics of Vibrio cholerae strains isolated in Angola. Pathol Biol (Paris). 1992; 40(5):561-5. MID:1495844

35. Ceccarelli D, Anna S, Joana S, Piero C, Mauro M. New Cluster of Plasmid-Located Class 1 Integrons in Vibrio cholerae O1 and a dfrA15 Cassette-Containing Integron in Vibrio parahaemolyticus Isolated in Angola. Antimicrobial Agents and Chemotherapy, July 2006. 50(7): 2493–2499.

36. The Global Antibiotic Resistance Partnership (GARP), Kenya, 2011

37. Emacar J, Okemo P, Gatheri G, Kariuki S. Antibiotic resistance patterns of Escherichia coli isolated from HIV-sero positive adults at Mbagathi District Hospital, Nairobi, Kenya. J Appl Biosciences 27: 1705 – 1714. ISSN 1997–5902

38. Ombui JN, Kimotho AM, Ndhuhi JG. Antimicrobial Resistance Patterns and Plasmid Profiles of Staphylococcus aureus Isolated from Milk and Meat. East African Medical Journal 2000. 77(9): 463–467.

39. Sang WK, Kariuki SM, Schnabel D, Boga HI, Waiyaki PG, Wamae CN. Antibiotic susceptibility of Enteric pathogens from the Maasai community, Narok and Kajiado Districts, Kenya. Afr J Health Sci. 2011; 19:74-79.

40. Anguzu, JR, Olila D. Drug sensitivity patterns of bacterial isolates from septic post-operative wounds in a regional referral hospital in Uganda. African Health Sciences 2007; 7(1): 148-154

41. Kiwanuka J, Mwanga J. Childhood bacterial meningitis in Mbarara Hospital, Uganda: antimicrobial susceptibility and outcome of treatment. Afri. Health Sci. 2001; 1(1): 9-11

42. Kitara LD, Anywar AD, Acullu D, Odongo-Aginya E, Aloyo J, Fendu M. Antibiotic susceptibility of Staphylococcus aureus in supplicative lesions in Lacor Hospital,
Uganda. African Health Sciences 2011; 11(S1): S34 - S39
43. Joloba ML, Bajaksouzian S, Palavecino E, Whalen C, Jacobs MR. High prevalence of carriage of antibiotic-resistant *Streptococcus pneumoniae* in children in Kampala Uganda. Int J Antimicrob Agents. 2001 17 (5):395-400. PMID:11337227
44. Messele G, Alebachew T. *Neisseria gonorrhoeae* isolates from Ethiopia: 2 Pair correlations between minimal inhibitory concentration values of five antibiotics and frequency of multiple antibiotic resistance Bulletin of the World Health Organization, 58 (1): 73-79 (1980)
45. Asrat D. *Shigella* and *Salmonella* serogroups and their antibiotic susceptibility patterns in Ethiopia. La Revue de Sante de la Mediterranee orientale, 2008; 14 (4)
46. Kibret M, Abera B. Antimicrobial susceptibility patterns of *E. coli* from clinical sources in northeast Ethiopia. African Health Sciences 2011; 11(S1): S40 - S45
47. Andargachew M, Afework K, Belay T. Bacterial isolates from cerebrospinal fluids and their antibiotic susceptibility patterns in Gondar University Teaching Hospital, Northwest Ethiopia. Ethiop J Health Dev. 2005; 19(2):160-164.
48. Getenet B, Wondewosen T. Bacterial Uropathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern in Jimma University Specialized Hospital, Southwest Ethiopia. Ethiop J Health Sci. 2011; 21(2)
49. United Nations Statistics Division. Standard country and area codes classification (M49). http://unstats.un.org/unsd/methods/m49/m49regin.htm
50. Vlieghe E, Phoba MF, Tamfun JM, Jacobs J. Antibiotic resistance among bacterial pathogens in Central Africa: a review of the published literature between 1955 and 2008, International Journal of Antimicrobial Agents (2008), doi:10.1016/j.ijantimicag.2009.04.015
51. Lamyaa S. and Rania S. Prevalence and antimicrobial resistance pattern of bacterial meningitis in Egypt. Annals of Clinical Microbiology and Antimicrobials 2009, 8:26 doi:10.1186/1476-0711-8-26
52. Ministry of Health and Population, Egypt: Enhanced Surveillance for Communicable Diseases, annual summary January-December 2000 report. [http://www.geis.fhp.osd.mil/GEIS/Train ing/EgyptSurv2000.htm].
53. Afifi S, Wasfy MO, Azab MA et al. Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998-2004). Eur J Clin Microbiol Infect Dis. 2007; 26 (5):331-40.
54. Ostroff SM, Harrison LH, Khalilah N, Assaad MT, Guirgis NI, Harrington S, el-Alamy M: Resistance patterns of *Streptococcus pneumoniae* and *Haemophilus influenzae* isolates recovered in Egypt from children with pneumonia. Clin Infect Dis 1996, 23(5):1069-74.
55. El Kholy A, Baseem H, Hall GS, Procop GW, Longworth DL. Antimicrobial resistance in Cairo, Egypt 1999-2000: A survey of five hospitals. J Antimicrob Chemother 2003, 51(3):625-30.
56. Borg MA, Tiemersma E, Scicluna E et al. Prevalence of penicillin and erythromycin resistance among invasive *Streptococcus pneumoniae* isolates reported by laboratories in the southern and eastern Mediterranean region. Clin Microbiol Infect 2009, 15(3):232-7.
57. Youssef FG, El-Sakka H, Azab A, et al. Etiology, antimicrobial susceptibility profiles, and mortality associated with bacterial meningitis among children in Egypt. Ann Epidemiol 2004, 14(1):44-8.
58. Wasfy MO, Pimentel G, Abdel M, et al. Antimicrobial susceptibility and serotype distribution of streptococcus pneumoniae causing meningitis in Egypt, 1998-2003. J Antimicrob Chemother 2005; 55 (6):958-64.
59. El Kholy, Hadia B, Geraldine S, Gary W, David L. Longworth Antimicrobial resistance in Cairo, Egypt 1999–2000: a survey of five hospitals. Journal of Antimicrobial Chemotherapy (2003) 51, 625–630.
60. Okesola AO and Oni AA. Antimicrobial Resistance among Common Bacterial Pathogens in South Western Nigeria. American-Eurasian J. Agric. and Environ. Sci., 2009 5 (3): 327-330
61. Iheanyi O, Femi A, Timothy A, Amusan A, Tolulope A, Ejembj I. Incidence of Multi-Drug Resistance (MDR) Organisms in Abeokuta, Southwestern Nigeria. Global Journal of Pharmacology, 3 (2): 69-80, 2009.
62. Iwalokun B, Gbenle G, Smith S, Ogunlewn A, Akinsinde K, Omonigbehin E.A.. Epidemiology of Shigellosis in Lagos, Nigeria: Trends in Antimicrobial Resistance. J Health Popul Nutr 2001; 19(3):183-190
63. Clarence S, Helen U, Nosakhare O. Multi-antibiotics-resistance plasmid profile of enteric pathogens in pediatric patients from Nigeria. Biokemistri. 2007; 19(1): 35-42
64. Rao GG. Risk factors for the spread of antibiotic-resistant bacteria. Drugs. 1998; 55(3): 323-30
65. Okeke IN, Laxminarayan R, Bhutta ZA, Duse Rao GG. Multi-drug resistant Acinetobacter anitratus species in neonatal and paediatric intensive care units in a developing country: concern about antimicrobial policies. Ann Trop Paediatr 2001; 21: 245-51.
66. Mohamed B, Said B, Cheiek S, Mireille D, Houria B, Aouatef K, Omar K, Naima E. Two-Year Surveillance of Antibiotic Resistance in Streptococcus pneumoniae in Four African Cities. Antimicrobial Agents and Chemotherapy, 2001; 45(2): 627-629.
67. Tolu O. Setting up an infection control programmes in the Hospital: Role of the policymakers. Journal of the Nigeria Infection Association. 1999; 2(1): 4-8
68. Shaheen M. Hospital infection control: Setting up a cost-effective programme, 1st ed. Oxford University Press, New York; 1992: 17-25.
69. Scott G. Infection control with limited resources. Africa Health. 1990; 13 (1):40–43.
70. Ogunsola FT, Oduyede O, Irebegb KC, Coker AO, Adetunji A. A review of nosocomial infections at Lagos University Teaching Hospital: Problems and strategies for improvement. Journal of the Nigerian Infection Association. 1998; 1(1):14-20.
71. Samuel S, Kayode O, Musa I et al. Nosocomial Infections and the Challenges of Control in Developing Countries. Afr. J. Cln. Exp. Microbiol. 2010; 11(2): 102-110
72. Adegoke A, Tom M, Okoh A, Jacob S. Studies on multiple antibiotic resistant bacterial isolated from surgical site infection. Scientific Research and Essays. 2010; 5(24): 3876-3881
73. Sani RA, Garba SA, Oyewole O. Antibiotic Resistance Profile of Gram Negative Bacteria Isolated from Surgical Wounds in Minna, Bida, Kontagora and Suleja Areas of Niger
State. American Journal of Medicine and Medical Sciences 2012, 2(1): 20-24
84. Olayinka AT, Onile BA, Olayinka BO. Prevalence of Multi-Drug Resistant *Pseudomonas aeruginosa* Isolates in Surgical Units of Ahmadu Bello University Teaching Hospital, Zaria, Nigeria: An Indication for Effective Control Measures Annals of African Medicine. 2004 3 (1): 13 - 16
85. Amin A, Kokwaro G, Antimalarial Drug Quality in Africa. J Clin Pharm Ther. 2007; 32(5): 429–440.
86. Cockburn P, Newton N, Agyarko K, Akunyili D, White J. The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers. PLoS Medicine 2005; 2: e100. [PubMed: 15755195]
87. WHO. Effective drug regulation: what can countries do? Geneva: 1999; 1-53.
88. MCA. Towards safe medicines. A guide to the control of safety, quality and efficacy of human medicines in the United Kingdom. Vol. Revised edition 1997. Medicines Control Agency (MCA); London: 1997; 1-93.
89. WHO. Guidelines for developing national drug policies. WHO. Geneva, 1988.
90. Jayasuriya DC. Regulation of pharmaceuticals in developing countries. Strategies for assurance of drug quality, safety, and efficacy. WHO, Geneva 1985; 51-62.
91. World Health Organization. Counterfeiting the counterfeits. WHO Drug Information. 1987; 1:195-196.
92. Hogerzeil HV, De-Goerje MJ, Abu-Reid. Stability of essential drugs in Sudan. Lancet. 1991; 338:754.
93. Arya SC. Inadvertent supply of substandard drugs. World Health Forum. 1995; 16:269.
94. Essack SY. Strategies for the Prevention and Containment of Antibiotic Resistance. SA Fam Pract 2006; 48(1): 51
95. Grimwade K, Gilks C. Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries. Curr Opin Infect Dis 2001;14: 507-12.
96. Sujit S, Emily SB, Annelies VR. Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic Review PLoS ONE | www.plosone.org, 2009; 4 (5): e5561
97. Braun MM, Kilburn JO, Smithwick RW, Coulibaly IM, Coulibaly D, et al. (1992) HIV infection and primary resistance to antituberculosis drugs in Abidjan, Cote d’Ivoire. Aids. 6: 1327–1330.
98. Chum HJ, O’Brien RJ, Chonde TM, Graf P, Rieder HL (1996). An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991–1993. Aids. 10: 299–309.
99. Iruka N, Adebayo L, Robert E. Socioeconomic and Behavioral Factors Leading to Acquired Bacterial Resistance to Antibiotics in Developing Countries. Emerging Infectious Diseases 1999; 5 (1): 18-27.
100. Nambatya J, Nyairo S, Bironse M, Kachwiya S, Musigunzi N, Kamulegeya A. Antibiotic use knowledge and behavior at a Ugandan University. Int J Infect Control. 2011, v7:i4 doi: 10.3396/ijic.V7i4.029.11
101. Victoria O, Tajudeen O. Antibiotic resistance of *Escherichia coli*, *Listeria* and *Salmonella* isolates from retail meat tables in Ibadan municipal abattoir, Nigeria. African Journal of Biotechnology. 2011; 10(30): 5795-5799.
102. Olayemi O, Olayinka B, Musa A. Evaluation of Antibiotic Self-Medication Pattern amongst Undergraduate Students of Ahmadu Bello University (Main Campus), Zaria. Research Journal of Applied Sciences Engineering and Technology. 2010; 2(1): 35-38.
103. Abdelmoneim A, Idris E, Lloyd M. Self-medication with Antibiotics and Antimalarials in the community of Khartoum State, Sudan. J Pharm Pharmaceut Sci. 2005; 8(2):326-331.